The 12-year-old firm raised $360,360,360 for its fifth fund. And there's a reason for that number.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...

Mariah is a Berlin-based writer with six years of experience in writing, localizing and SEO-optimizing short- and long-form content across multiple niches, including higher education, digital ...

Many developers share their LeetCode solutions on GitHub. Look for repositories that are well-organized by topic or problem number, have clear explanations, and show good code quality. Some popular ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...